Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 7, 2012, Pages 2393-2395

  Jia, Qiyan ^a   Jiang, Xifeng ^a   Yu, Fei ^b,c   Qiu, Jiayin ^c   Kang, Xiaoyu ^a   Cai, Lifeng ^a   Li, Lin ^c   Shi, Weiguo ^a   Liu, Shuwen ^c   Jiang, Shibo ^b,d   Liu, Keliang ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

1 Antitrypsin; Entry inhibitors; HIV 1; Peptides

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMINO ACID; CYCLOPEPTIDE; PEPTIDE; SERINE PROTEINASE INHIBITOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; VIRUS ENTRY;

ALPHA 1-ANTITRYPSIN; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CELL LINE, TUMOR; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES, CYCLIC; PROTEIN STRUCTURE, TERTIARY; T-LYMPHOCYTES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84862807224     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.02.037     Document Type: Article

References (25)

1. G.A. Silverman, P.I. Bird, R.W. Carrell, F.C. Church, P.B. Coughlin, P.G. Gettins, J.A. Irving, D.A. Lomas, C.J. Luke, R.W. Moyer, P.A. Pemberton, E.R. O'Donnell, G.S. Salvesen, J. Travis, and J.C. Whisstock J. Biol. Chem. 276 2001 3329
2. E.C. Lewis, M. Mizrahi, M. Toledano, N. DeFelice, J.L. Wright, A. Churg, L. Shapiro, and C.A. Dinarello Proc. Natl. Acad. Sci. U.S.A. 105 2008 16236
3. M. Koulmanda, M. Bhasin, L. Hoffman, Z. Fan, A. Qipo, H. Shi, S. Bonner-Weir, P. Putheti, N. Degauque, and T.A. Libermann Proc. Natl. Acad. Sci. U.S.A. 105 2008 16242
4. I.M. Nita, D. Serapinas, and S.M. Janciauskiene Int. J. Biochem. Cell Biol. 39 2007 1165
5. K. Normandin, B. Peant, C.L. Page, M. Ladurantaye, V. Ouellet, P.N. Tonin, D.M. Provencher, and A.M. Mes-Masson Clin. Exp. Metastasis 27 2010 55
6. T. Hattori, A. Koito, K. Takatsuki, H. Kido, and N.N. Katunuma FEBS Lett. 248 1989 48
7. E.D. Anderson, L. Thomas, J.S. Hayflick, and G. Thomas J. Biol. Chem. 268 1993 24887
8. L. Shapiro, G.B. Pott, and A.H. Ralston FASEB J. 15 2001 115
9. P. Cordelier, and D.S. Strayer Biochim. Biophys. Acta. 1638 2003 197
10. G. Joslin, R.J. Fallon, J. Bullock, S.P. Adams, and D.H. Perlmutter J. Biol. Chem. 266 1991 11282
11. L.F. Congote Biochem. Biophys. Res. Commun. 343 2006 617
12. M. Rhee, and P. Davis J. Biol. Chem. 281 2006 1233
13. J. Munch, L. Standker, K. Adermann, A. Schulz, M. Schindler, R. Chinnadurai, S. Pohlmann, C. Chaipan, T. Biet, T. Peters, M. Bernd, D. Wilhelm, H. Lu, W. Jing, S. Jiang, W.G. Forssmann, and F. Kirchhoff Cell 129 2007 263
14. Shi, W.; Qi, Z.; Pan, C.; Xue, N; Debnath A. K.; Qie, J.; Jiang, S.; Liu, K.; Biochemical and Biophysical Research Communications 2008, 374, 767. These peptides were synthesized with an Fmoc strategy using Rink Amide Resin. Their N- and C-termini were acetylated and amidated, respectively. All the peptides were purified by reverse phase high performance liquid chromatography to >95% homogeneity. The molecular weight of the peptides was confirmed by MALDI-TOF-MS (Autoflex III, Bruker Daltonics).
15. 50) was calculated by using the software Calcusyn.
16. J.A. Camarero, and T.W. Muir J. Am. Che. Soc. 121 1999 5597
17. F. Yokoyama, N. Suzuki, M. Haruki, N. Nishi, S. Oishi, N. Fujii, A. Utani, H.K. Kleinman, and M. Nomizu Biochemistry 43 2004 13590
18. R. Perlikowska, J.C. Do-Rego, A. Cravezic, J. Fichna, A. Wyrebska, G. Toth, and A. Janecka Peptides 31 2010 339
19. D.H. Perlmutter, G. Joslin, P. Nelson, C. Schasteen, S.P. Adams, and R.J. Fallon J. Biol. Chem. 265 1990 16713
20. M.A. Camerino, D. Kong, D.K. Chalmers, and P.E. Thompson Int. J. Pept. Res. Ther. 14 2008 323
21. S.K. Sia, P.A. Carr, A.G. Cochran, V.N. Malashkevich, and P.S. Kim Proc. Natl. Acad. Sci. U.S.A. 99 2002 14664
22. 4 at the final concentration of 2 mg/mL, followed by addition of 3 equiv TCEP and adjustment of the pH to 7.0. The reaction was monitored by HPLC. The cyclic peptides were then purified by reverse phase HPLC to >95% homogeneity. The molecular weight of the peptides was confirmed by MALDI-TOF-MS (Autoflex III, Bruker Daltonics).
23. 14
24. Chou T. C.; Hayball, M. P. 1991. CalcuSyn: Windows software for dose effect analysis. BIOSOFT, Ferguson, MO 63135, USA.
25. He Y.; Liu S.; Li J.; Lu H.; Qi Z.; Liu Z.; Debnath A. K.; Jiang S. J. Virol. 2008, 82, 11129. For determining the inhibitory activity of the peptides on infection by a pseudovirus expressing the envelop protein gp160 of the HIV-1 R5 virus SF162, U87-CCR5 cells (1 × 104/well) were seeded in 96-well plates and grown overnight. A peptide at indicated concentration was incubated with pseudotyped particles For construction and expression of a pseudovirus expressing the envelop protein gp160 of the HIV-1 R5 virus SF162, (1 ng p24/well) for 30 min at 37 °C. Subsequently, the virus-compound mixture was transferred to the cells and incubated for an additional 48 h. Cells were washed with PBS and lysed with the lysing reagent included in the luciferase kit (Promega, Madison, WI). Aliquots of cell lysates were transferred to luminometer plates, followed by the addition of luciferase substrate. The luciferase activity was measured in a microplate luminometer (Genios Pro, Tecan).